logo
Patients will need extensive support after involuntary addiction treatment: Alberta agency

Patients will need extensive support after involuntary addiction treatment: Alberta agency

CBC24-03-2025
Social Sharing
An Alberta Crown corporation that studies addiction recommends that any involuntary treatment be done for longer time periods because shorter stays seem ineffective.
In a paper released on Friday, the Canadian Centre of Recovery Excellence (CoRE), an Alberta Crown corporation, says the province will need to provide a robust network of support after patients leave forced treatment centres if they want the approach to succeed.
"The goal is to say, 'Hey, look across the spectrum of things we can do. What's the best in class, and are there ways that we can offer this to the people who need it most?' " said Dr. Nathaniel Day, CoRE's scientific director and one of the paper's authors.
The United Conservative Party government in the 2023 provincial election pledged to introduce involuntary addiction treatment for adults.
The provincial government created CoRE last year to study the best ways to support addiction recovery.
CoRE spokesperson Katy Merrifield said the government asked CoRE to review existing evidence and similar models of involuntary treatment to advise the government on how to develop an Alberta program.
The government has said it will introduce what it calls "compassionate intervention" legislation this year, which would allow police, doctors, family members or a guardian to request mandatory drug treatment for a person with severe addiction.
Provincial data shows 1,182 people died of opioid poisoning in 2024 in Alberta. Although it was a 37 per cent drop from the previous year, an average of three people are dying each day.
Day and his co-authors reviewed research on involuntary treatment, which the paper calls "civil commitment," in Canada, the U.S., some European countries and Australia.
It says most of the research was done before the development of opioid agonist treatment, which consists of long-acting medications that can cut poisoning deaths by half.
The authors also looked at professionals such as nurses, pilots, doctors and dentists who were required to take drug treatment programs to retain their professional credentials or jobs. It's a group the report acknowledges is not a perfect comparison to the general population.
They found the "current literature is not adequate to determine the effect of civil commitment in general, or determine which interventions are beneficial and to what degree."
In the studies that tracked post-treatment deaths, five-to-10 per cent of people died.
The authors also found many patients who initially were forced into treatment were later compliant with recovery and grateful for the help.
They recommend keeping patients in treatment as long as the person needs, offering medications to prevent overdoses, help people find training or jobs, and offer follow-up therapy, peer support and check ins to help keep them sober.
The province should accept that some patients will have permanent brain damage and impairments and long-term mental illness and may need lifelong support, the says.
The report says patients should have access to appeals and review mechanisms for involuntary treatment, but doesn't recommend timelines.
Day said the province shouldn't be deterred by an absence of comprehensive studies.
"Just because something does not have clear literature, doesn't mean it isn't valuable," he said.
Psychiatrist worries about unaddressed harms
Dr. David Crockford, a University of Calgary psychiatrist who specializes in addiction medicine, and was not involved in the report, says the document fails to address some of the risks of involuntary therapy.
He said data from Australia shows a disproportionate number of Indigenous people and new immigrants in forced treatment.
Detaining and treating people who have already experienced trauma could lead to further feelings of distrust, and prevent some of those people from voluntarily seeking medical help in the future, he said.
There should also be short timelines in which patients can appeal their detention, like those included in the province's mental health legislation, he said.
"People can choose not to get the measles vaccine, can choose not to get the COVID vaccine and their rights are being vehemently upheld," he said. "And yet, people who are the most vulnerable are having their rights taken away from them, and being subject potentially to something which might be damaging."
Post-treatment overdose rates can also be higher in patients who were involuntarily treated compared to those who willingly participated, he said.
Crockford said it's unclear whether the recommendations apply to any substance addiction, including tobacco or cannabis, or just opioids. He said the authors don't define a "severe" addiction that could warrant involuntary treatment.
He said patients seeking voluntary treatment in Alberta still struggle getting access to detox and longer-term inpatient treatment centres. He said that system should be expanded before forcing people into treatment.
In a statement, Hunter Baril, press secretary to the minister of mental health and addictions, did not directly say how the government will use the CoRE recommendations.
"No jurisdiction in the world has built the system Alberta is building to bring people out of addiction and into recovery, including through treatment orders for those who have become a danger to themselves or others," the statement said.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

EU chief's texts to a pharma boss during pandemic were likely erased, the NYT reports
EU chief's texts to a pharma boss during pandemic were likely erased, the NYT reports

Toronto Star

time2 days ago

  • Toronto Star

EU chief's texts to a pharma boss during pandemic were likely erased, the NYT reports

BRUSSELS (AP) — Text messages exchanged between European Commission President Ursula von der Leyen and a pharmaceutical boss during the COVID-19 pandemic were seen by her top adviser and have likely been destroyed, the New York Times reported Friday. Von der Leyen and Pfizer CEO Albert Bourla exchanged the messages as COVID-19 ravaged European communities from Portugal to Finland and the EU scrambled to buy millions of hard to find vaccines. She was under intense scrutiny to deliver.

FILAMENT HEALTH ANNOUNCES FIRST-EVER COMPASSIONATE USE APPROVAL FOR PSILOCYBIN IN THE EUROPEAN UNION
FILAMENT HEALTH ANNOUNCES FIRST-EVER COMPASSIONATE USE APPROVAL FOR PSILOCYBIN IN THE EUROPEAN UNION

Cision Canada

time3 days ago

  • Cision Canada

FILAMENT HEALTH ANNOUNCES FIRST-EVER COMPASSIONATE USE APPROVAL FOR PSILOCYBIN IN THE EUROPEAN UNION

Filament's botanical psilocybin drug candidate PEX010 to be administered in Germany for treatment-resistant depression VANCOUVER, BC, /CNW/ - Filament Health Corp. (OTC:FLHLF) (" Filament" or the " Company"), a clinical‐stage natural psychedelic drug development company, today announced the first-ever approval for compassionate use of psilocybin in the European Union (EU). The Company's botanical psilocybin drug candidate, PEX010, has been authorized for administration to a patient suffering from treatment-resistant depression (TRD) in Germany. The approval was granted under Germany's compassionate use framework and marks the first time psilocybin will be prescribed outside of a clinical trial in the EU. The treatment will be conducted by Dr. Gerhard Gründer at the Central Institute of Mental Health, Department of Molecular Neuroimaging. "This is a landmark moment for the field of psychedelic medicine in the European Union. Treatment-resistant depression affects up to 30% of individuals diagnosed with major depressive disorder and remains one of the most difficult psychiatric conditions to treat. Psilocybin has demonstrated significant promise as a novel therapeutic option, and this approval marks an important step toward expanding access for those in urgent need," said Dr. Gerhard Gründer. "I am honoured to play a role in expanding European access to psilocybin and grateful to the team at Filament Health for their support." "The approval of PEX010 for this milestone moment in European psilocybin access reinforces Filament's position as the world's leading supplier of GMP-quality psychedelic drug candidates," said Benjamin Lightburn, Co-Founder and Chief Executive Officer at Filament Health. "We're incredibly proud that our drug product will be the first psilocybin to be administered under compassionate use in the EU. It's a validation of Filament's ongoing efforts to make safe, standardized psychedelic medicines available to those who need them most." ABOUT FILAMENT HEALTH (OTC:FLHLF) Filament Health is a clinical-stage natural psychedelic drug development company. We believe that safe, standardized, naturally-derived psychedelic medicines can improve the lives of many, and our mission is to see them in the hands of everyone who needs them as soon as possible. Filament's platform of proprietary intellectual property enables the discovery, development, and delivery of natural psychedelic medicines for clinical development. We are paving the way with the first-ever natural psychedelic drug candidates. Learn more at and on X, Instagram, and LinkedIn. FORWARD LOOKING INFORMATION Certain statements and information contained in this press release and the documents referred to herein may constitute "forward‐looking statements" and "forward‐looking information," respectively, under Canadian securities legislation. Generally, forward‐looking information can be identified by the use of forward‐looking terminology such as, "expect", "anticipate", "continue", "estimate", "may", "will", "should", "believe", "intends", "forecast", "plans", "guidance" and similar expressions are intended to identify forward‐looking statements or information. The forward‐looking statements are not historical facts, but reflect the current expectations of management of Filament regarding future results or events and are based on information currently available to them. Certain material factors and assumptions were applied in providing these forward‐looking statements. Forward‐looking statements regarding the Company are based on the Company's estimates and are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of Filament to be materially different from those expressed or implied by such forward‐looking statements or forward‐looking information, including the timing and results of clinical trials, the ability of the parties to receive, in a timely manner and on satisfactory terms, the necessary regulatory, court and shareholders approvals; the ability of the parties to satisfy, in a timely manner, the other conditions to the completion of the proposed business combination; other expectations and assumptions concerning the transactions contemplated in the proposed business combination; the available funds of the parties and the anticipated use of such funds; the availability of financing opportunities; legal and regulatory risks inherent in the psychedelic drug development industry; risks associated with economic conditions, dependence on management and currency risk; risks relating to U.S. regulatory landscape; risks relating to anti-money laundering laws and regulation; other governmental and environmental regulation; public opinion and perception of the psychedelic drug development industry; risks related to the economy generally; risk of litigation; conflicts of interest; risks relating to certain remedies being limited and the difficulty of enforcement of judgments and effect service outside of Canada; and risks related to future acquisitions or dispositions. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward‐ looking statements and forward‐looking information. Filament will not update any forward‐looking statements or forward‐looking information that are incorporated by reference herein, except as required by applicable securities laws.

Cata-Kor Receives Alchemist Assured Certification for Its NAD+ Core Supplement
Cata-Kor Receives Alchemist Assured Certification for Its NAD+ Core Supplement

Globe and Mail

time5 days ago

  • Globe and Mail

Cata-Kor Receives Alchemist Assured Certification for Its NAD+ Core Supplement

Certification Confirms Quality and Transparency Standards for Cata-Kor's U.S.-Made Liposomal NAD+ Formula Miami, Florida--(Newsfile Corp. - July 29, 2025) - Cata-Kor, an innovation-driven supplement company behind the science-backed NAD+ Core formula, announced it has received the Alchemist Assured certification - a trusted signal of the company's quality, safety, and manufacturing integrity. NAD+ Core To view an enhanced version of this graphic, please visit: The Alchemist Assured certification, issued by botanical testing leader Alkemist Labs, is granted only to dietary supplement brands that meet stringent third-party criteria in purity, transparency, and Good Manufacturing Practices (GMP). The program helps consumers, retailers, and industry partners identify brands that meet high standards of quality and scientific integrity. "In an industry where self-regulation is often the norm, this certification provides a rare level of external validation," said Alex Rahacheuski, Quality Control Specialist at Cata-Kor. "Achieving the Alchemist Assured standard demonstrates our long-term commitment to clean science, full transparency, and customer trust." To qualify for certification, Cata-Kor submitted its NAD+ Core supplement for independent lab analysis and a full compliance audit. The process required third-party testing to confirm ingredient identity, potency, and purity - ensuring that all components were accurately labeled and free from contaminants. It also included transparent labeling practices, such as publishing consumer-friendly versions of lab results and Certificates of Analysis (COAs) to provide clarity on all active and inactive ingredients. In addition, the company retained full technical COAs from Alkemist Labs while making simplified summaries available to the public. The NAD+ Core supplement, which has received Alchemist Assured certification, is designed to support cellular energy and longevity through Cata-Kor's proprietary LipoNAD+ delivery system - a lipid-based formulation engineered to bypass stomach breakdown and enhance absorption in the intestines. Cata-Kor's transparent approach and consistent scientific data were key to meeting certification standards. "This milestone is not just symbolic. It gives us a major edge in a competitive, trust-sensitive market," added Rahacheuski. The Alchemist Assured program is awarded selectively and serves as a trusted mark of scientific rigor and clean-label compliance. This certification is a critical step in Cata-Kor's long-term strategy to scale its science-driven product portfolio and enter regulated international markets. The company is currently preparing additional product launches and research collaborations aimed at advancing longevity and cellular health. "This achievement is a cornerstone in our global growth strategy," Rahacheuski said. "We're not here to follow trends - we're here to raise the bar for science and transparency in wellness." About Cata-Kor Cata-Kor is a U.S.-based supplement company developing advanced nutraceutical technologies that target cellular health, healthy aging, and performance optimization. The company's production and testing are fully located in the United States. Learn more at Always consult with a healthcare provider before starting new dietary supplements.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store